3 stories
GLP-1 drugs have started reshaping consumer food and beverage spending — and the food industry has noticed. Coverage on this site tracks public statements from food companies, restaurant analytics, and grocery-spending data showing reduced calorie purchases among GLP-1 users.
Notable threads: BeverageDaily, Food Navigator, and other trade outlets quantifying GLP-1 impact on consumer purchase patterns; analyst reports projecting that one in ten American adults already on GLP-1s could expand to 25% with next-generation peptide drugs (retatrutide, Foundayo); and the food industry's strategic response — reformulation, smaller portions, and adjacent product categories.
Stories here cover the consumer-spending data and the food company responses. See #consumer-trends for related coverage.
Wall Street bets GLP-1 drugs will transform food. Packaged-food giants are down 50%+ from peaks. Goldman projects these drugs could add over 1% to GDP if adoption reaches 60 million Americans by 2028.
With one in ten American adults already on GLP-1 drugs, next-generation medications including Foundayo and retatrutide could reach the ~25% of patients who don't respond to current GLP-1 monotherapies.
CNBC reports that within six months of starting a GLP-1 medication, households reduce grocery spending by 5.3% and fast-food spending by 8%. Dinner traffic has fallen 6% among regular users, with ultra-processed food spending down 10%. Food companies are racing to develop protein- and fiber-rich 'GLP-1 friendly' products.